NONOF News and Press, Novo-Nordisk A/S From 03/28/24

2024-03-28 10:00:53 ET More on CVS, Elevance Health, etc. Elevance: A Healthy Dose Of Dividend Growth Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential ...

2024-03-27 19:50:00 ET Summary Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said that the GLP-1 market could exceed $100 billion b...

2024-03-27 11:55:00 ET Summary Giverny Capital is a Montreal-based investment advisor specializing in private wealth management that also offers financial planning services. For the year ending December 31st 2023, the return for the Rochon Global Portfolio was 24.3% versus 17.5% f...

2024-03-27 08:26:15 ET More on Altimmune Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment Thoroughly Derisked, Altimmune Is Now A Great Buy Altimmune Q4 202...

2024-03-26 14:15:37 ET More on Amazon, Eli Lilly, etc. Amazon: Still Cheap Even After Robust Rally Amazon Faces Off Against Temu: Who Will Win? Eli Lilly: The Party Is Not Over Amazon making same-day prescription delivery available in NYC and LA Novo ...

2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...

2024-03-21 13:35:23 ET More on Eli Lilly, Novo Nordisk, etc. Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Confer...

2024-03-20 13:09:31 ET More on Eli Lilly, Novo Nordisk, etc. Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Confer...

2024-03-18 10:02:54 ET Summary US providers for kidney dialysis and renal solutions, such as DaVita Inc. and Novo Nordisk, have seen significant gains in the past year. DaVita's decision to expand its renal care operations in Latin America, particularly in Brazil, Colombia, Ecuado...

2024-03-16 12:57:30 ET More on Madrigal Pharmaceuticals Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Ra...